EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Pyrotinib inhibits the tumorigenicity of HER2-positive non-small cell lung cancer by inducing ARIH1/ubiquitin/lysosome-dependent degradation of HER2

Xiyue Li, Jiehong Wang, Shu Li, Jing Fang, Yue Hao, Chunwei Xu, You Shu, Hong Shu, Jiaojiao Chen, Naiyan Lu, Xue Zhu, Ke Wang und 1 weitere

Cellular Oncology · 2025

DOI: 10.1007/s13402-025-01107-z ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cellular Oncology, 2025. Verfasst von Xiyue Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, 214063, Ji…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Lysosomes. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Jiangsu Provincial Natural Science Foundation, Scientific Research Project of Jiangsu Commission of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Non-small cell lung cancer (NSCLC), accounting for the majority of lung cancer, is the leading cause of cancer death worldwide, and molecular targeted drugs promote greatly advance in the treatment of this disease. Overexpression of human epidermal growth factor receptor 2 (HER2) occurs in 1-5% of NSCLC cases, correlating with poorer outcomes and lack of approved targeted drugs. Pyrotinib is an irreversible HER2 receptor tyrosine kinase inhibitor developed for the treatment of HER2-positive advanced solid tumors; however, the comprehensive exploration of Pyrotinib's anti-tumor mechanism in HER2-positive NSCLC cells needs further explored. METHODS: Using HER2-high copy number NSCLC cancer cell lines, primary cells and subcutaneous tumor models in nude mice, we systematically evaluated pyrotinib’s anti-tumor activity through viability assays, Colony formation assay, and apoptosis analysis. Mechanistic studies included co-immunoprecipitation, Quantitative reverse transcription-PCR, ubiquitination assays, and Liquid Chromatography-Tandem Mass Spectrometry analysis. RESULTS: This study revealed that Pyrotinib suppressed the tumorigenicity of HER2-positive NSCLC cells (H2170 and Calu-3 cell lines) by promoting HER2 degradation, inhibiting HER2 downstream signalings, inducing cell apoptosis, and ultimately triggering cell death. However, however, this drug presented low cytotoxic effects on H1299 (low-HER2 cell line) and BEAS-2B (human lung epithelial cell line) cells. Mechanistic analyses revealed that Pyrotinib facilitated HER2 degradation by inducing ubiquitination of HER2, enhancing interaction between ARIH1 and HER2, and subsequent triggering lysosomal degradation of HER2. Furthermore, Pyrotinib suppressed tumor growth of HER2-positive NSCLC xenografts, in an ARIH1-dependent manner. CONCLUSION: Pyrotinib enhances the binding of the E3 ubiquitin ligase ARIH1 to HER2, promoting HER2 ubiquitination and endocytosis, which leads to degradation via the lysosomal pathway. Our data explain why Pyrotinib has shown good efficacy in clinical trials and provide new insights into the application of Pyrotinib in HER2-positive non-small cell lung cancer. CLINICAL TRIAL NUMBER: Not applicable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsErb-b2 Receptor Tyrosine KinasesLysosomesAminoquinolinesAcrylamidesProteolysisUbiquitinUbiquitin-Protein LigasesCarcinogenesisPyrazinesHumansAnimalsCell Line, TumorMice, NudeApoptosisXenograft Model Antitumor AssaysFemaleUbiquitinationMiceMice, Inbred BALB CSignal TransductionTyrosine Kinase Inhibitors

Substanzen

pyrotinibErb-b2 Receptor Tyrosine KinasesAminoquinolinesAcrylamidesUbiquitinERBB2 protein, humanUbiquitin-Protein LigasesPyrazinesTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, 214063, Jiangsu Province, China.
  • Wuxi School of Medicine, Jiangnan University, Wuxi, 214122, Jiangsu Province, China.
  • Department of Respiratory Medicine, Affiliated Hospital of Jiangnan University, Wuxi, 214000, Jiangsu Province, China.
  • Department of Radiopharmaceuticals, School of Pharmacy, Nanjing Medical University, Nanjing, 211166, Jiangsu Province, China.
  • Department of Respiratory Medicine, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, 210002, Jiangsu Province, China.
  • Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou, 310022, Zhejiang Province, China.

Förderung

  • National Natural Science Foundation of China
  • Jiangsu Provincial Natural Science Foundation
  • Scientific Research Project of Jiangsu Commission of Health
  • Wuxi Science and Technology Development fund
  • Major Project of Wuxi Municipal Health Commission
  • the Project of Jiangsu Administration of Traditional Chinese Medicine
  • Wuxi Association for Science and Technology
  • Scientific Research Foundation of Jiangsu Institute of Nuclear Medicine

Zitieren

APA

Li, X., Wang, J., Li, S., Fang, J., Hao, Y., Xu, C., Shu, Y., Shu, H., Chen, J., Lu, N., Zhu, X., Wang, K., & Wang, X. (2025). Pyrotinib inhibits the tumorigenicity of HER2-positive non-small cell lung cancer by inducing ARIH1/ubiquitin/lysosome-dependent degradation of HER2. Cellular Oncology. https://doi.org/10.1007/s13402-025-01107-z

Vancouver

Li X, Wang J, Li S, Fang J, Hao Y, Xu C, et al. Pyrotinib inhibits the tumorigenicity of HER2-positive non-small cell lung cancer by inducing ARIH1/ubiquitin/lysosome-dependent degradation of HER2. Cellular Oncology. 2025. doi:10.1007/s13402-025-01107-z

BibTeX
@article{Li2025,
  author = {Li, Xiyue and Wang, Jiehong and Li, Shu and Fang, Jing and Hao, Yue and Xu, Chunwei and Shu, You and Shu, Hong and Chen, Jiaojiao and Lu, Naiyan and Zhu, Xue and Wang, Ke and Wang, Xun},
  title = {Pyrotinib inhibits the tumorigenicity of HER2-positive non-small cell lung cancer by inducing ARIH1/ubiquitin/lysosome-dependent degradation of HER2},
  journal = {Cellular Oncology},
  year = {2025},
  doi = {10.1007/s13402-025-01107-z}
}
Kostenlos starten →